Oral Administration of a Seed-based Bivalent Rotavirus Vaccine Containing VP6 and NSP4 Induces Specific Immune Responses in Mice

Feng, Hao; Li, Xin; Song, Weibin; Duan, Mei; Chen, Hong; Wang, Tao; Dong, Jiangli

doi:10.3389/fpls.2017.00910

Cited by 24 publications

(12 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Edible vaccines are potential developing direction of vaccination, and much effort has been made on the rotavirus vaccines. Production of rotavirus VP6 in transgenic plants such as potato, alfalfa, tabaco and maize has been achieved, and gavage of the extracts with adjuvants (CT, LT or CpG et al) in lactating mice induced passive protection of offspring [36–39]. These are successful effort for developing edible vaccines, but the extracts and adjuvant are not welcomed by the infants and the purification is expected to be complex and difficult.…”

Section: Discussionmentioning

confidence: 99%

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

Cui

Wang

et al. 2019

J Nanobiotechnol

View full text Add to dashboard Cite

BackgroundRotavirus is the leading cause of severe dehydrating diarrhea in young children and the inner capsid protein VP6 is a potential vaccine candidate that can induce cross-protective immune responses against different Rotavirus strains. The use of ferritin nanoparticles as the scaffold of the antigen can improve the immunogenicity of the subunit vaccines and provide broader protection. We here present a non-live and self-assemble recombinant rotavirus VP6–ferritin (rVP6–ferritin) nanoparticle vaccine.ResultsThe rVP6–ferritin nanoparticles were expressed in E. coli and self-assembled to uniform spherical structure which similar to ferritin, and oral administration of them induced efficient humoral and mucosal immunogenicity in mice. The nanoparticles were further transgenically expressed in the milk of mice, and pup mice breastfed by transgenic rVP6–ferritin mothers had strongly induced immunogenicity and—compared to pups breastfed by wild type mothers—the proportion of rotavirus challenged pups with diarrhea symptoms, the duration and intensity of the diarrhea, and the deleterious effects on overall growth resulting from the diarrhea were all significantly reduced.ConclusionsThese results suggest that this recombinant VP6–ferritin nanoparticle vaccine can efficiently prevent the death and malnutrition induced by the rotavirus infection in infants and is a promising candidate vaccine for rotavirus.Electronic supplementary materialThe online version of this article (10.1186/s12951-019-0446-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

Cui

Wang

et al. 2019

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…In particular, Jalilvand et al (2015) have excellently summed up the main contributions of different groups that have worked with the VP6 protein of RVA as an immunogen. Also, recent publications have used VP6 protein as an immunogen proposed for vaccine development against RVA following different strategies (Feng et al, 2017;Afchangi et al, 2017). On the other hand, given the degree of sequence conservation observed within the same group, VP6 is an excellent candidate for an immunogen since it would be able to confer heterotypic protection.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein

Rota

Palacios

Temprana

et al. 2018

Journal of Virological Methods

View full text Add to dashboard Cite

Group C Rotavirus (RVC) has been associated globally with sporadic outbreaks of gastroenteritis in children and adults. RVC also infects animals, and interspecies transmission has been reported as well as its zoonotic potential. Considering its genetic diversity and the absence of effective vaccines, it is important and necessary to develop new generation vaccines against RVC for both humans and animals. The aim of the present study was to develop and characterize an HSV-1-based amplicon vector expressing a human RVC-VP6 protein and evaluate the humoral immune response induced after immunizing BALB/c mice. Local fecal samples positive for RVC were used for isolation and sequencing of the vp6 gene, which phylogenetically belongs to the I2 genotype. We show here that cells infected with the HSV[VP6C] amplicon vector efficiently express the VP6 protein, and induced specific anti-RVC antibodies in mice immunized with HSV[VP6C], in a prime-boost schedule. This work highlights that amplicon vectors are an attractive platform for the generation of safe genetic immunogens against RVC, without the addition of external adjuvants.

show abstract

“…For this group, several studies have pointed out that the VP6 protein confers protection against infection in some animal models, despite not inducing neutralizing antibodies. In particular, Jalilvand S et al RVA following different strategies (Feng et al, 2017;Afchangi et al, 2017). On the other hand, given the degree of sequence conservation observed within the same group, VP6 is an excellent candidate for an immunogen since it would be able to confer heterotypic protection.…”

Section: Discussionmentioning

confidence: 99%

Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains

Ibáñez

Rojas

Mattion

2018

Vaccine

View full text Add to dashboard Cite

H3N8 influenza virus strains have been associated with infectious disease in equine populations throughout the world. Although current vaccines for equine influenza stimulate a protective humoral immune response against the surface glycoproteins, disease in vaccinated horses has been frequently reported, probably due to poor induction of cross-reactive antibodies against non-matching strains. This work describes the performance of a recombinant protein vaccine expressed in prokaryotic cells (ΔHAp) and of a genetic vaccine (ΔHAe), both based on the conserved stem region of influenza hemagglutinin (HA) derived from A/equine/Argentina/1/93 (H3N8) virus. Sera from mice inoculated with these immunogens in different combinations and regimes presented reactivity in vitro against highly divergent influenza virus strains belonging to phylogenetic groups 1 and 2 (H1 and H3 subtypes, respectively), and conferred robust protection against a lethal challenge with both the homologous equine strain (100%) and the homosubtypic human strain A/Victoria/3/75 (H3N2) (70-100%). Animals vaccinated with the same antigens but challenged with the human strain A/PR/8/34 (H1N1), belonging to the phylogenetic group 1, were not protected (0-33%). Combination of protein and DNA immunogens showed higher reactivity to non-homologous strains than protein alone, although all vaccines were permissive for lung infection.

show abstract

Oral Administration of a Seed-based Bivalent Rotavirus Vaccine Containing VP6 and NSP4 Induces Specific Immune Responses in Mice

Cited by 24 publications

References 63 publications

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

A milk-based self-assemble rotavirus VP6–ferritin nanoparticle vaccine elicited protection against the viral infection

Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein

Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains

Contact Info

Product

Resources

About